ISSN:
1279-8509
Keywords:
CLL
;
Chlorodeoxyadenosine
;
therapy
;
remission
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract 2-Chlorodeoxyadenosine (2-CdA) was studied as initial therapy in patients with advanced and/or progressive chronic lymphocytic leukaemia using a shortened dosage schedule of 0.14 mg/kg/day by 2 hour IV infusion on 5 consecutive days. Thirty-four patients were treated, 25 males and 9 females (M:F = 2.7:1), with a median age of 58.8 years (range 3979). Distribution by Rai stage was I-2; II-16; III-9 and IV-7; and Binet: A-4; B-16; and C-14. ECOG performance status was 0-24; 1-9; 2-0; 3-1. All patients have completed study and have a minimum of 12 months follow-up. Patients came off study as follows: completed 3 or more cycles of treatment 26; progressive disease 1; toxicity 5; other 1; early death 1. Thirty-one patients remain alive with three deceased; one at day 4 (ECOG 3), while the other two occurred off-study. Thirty-three patients received at least one full cycle of treatment and a decrease of 〉 50% in the lymphocyte count occurred in all 33 (mean pre- and post-treatment of 89.0 and 7.9 × 109/L, respectively). Responses were evaluable in 32 and classified according to the National Cancer Institute Criteria (1988) as follows: complete remission (CR) 8 (25%); partial response (PR) 20 (62.5%); non-response (NR) 3; progressive disease (PD) 1. A majority of CRs showed residual CLL cells by histologic (nodules in 7/8) or phenotypic (6/8) criteria. The 32 evaluable patients had an overall response rate of 87.5% and a failure rate of 12.5%. Toxicity included infection 12; grade III or IV thrombocytopenia 2; and autoimmune haemolysis 1. Analysis with duration of response, at average 20 months (minimum 12 months) follow-up, will be presented. 2-CdA given by a shortened infusion schedule over 5 days results in a high response rate.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s00282-997-0083-7
Permalink
